<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>GPA Clinical Reference | Granulomatosis with Polyangiitis</title>
    <style>
        /* ========================================
           CSS VARIABLES & THEME
           ======================================== */
        :root {
            /* Semantic Color Palette */
            --red-primary: #D32F2F;
            --red-light: #FFEBEE;
            --red-dark: #B71C1C;
            --green-primary: #2E7D32;
            --green-light: #E8F5E9;
            --green-dark: #1B5E20;
            --blue-primary: #1565C0;
            --blue-light: #E3F2FD;
            --blue-dark: #0D47A1;
            
            /* Neutrals */
            --gray-900: #212121;
            --gray-700: #616161;
            --gray-500: #9E9E9E;
            --gray-300: #E0E0E0;
            --gray-100: #F5F5F5;
            --white: #FFFFFF;
            
            /* Spacing & Sizing */
            --radius-sm: 4px;
            --radius-md: 8px;
            --radius-lg: 12px;
            --shadow-sm: 0 1px 3px rgba(0,0,0,0.08);
            --shadow-md: 0 4px 12px rgba(0,0,0,0.1);
            --shadow-lg: 0 8px 24px rgba(0,0,0,0.12);
        }

        /* ========================================
           BASE STYLES
           ======================================== */
        * {
            box-sizing: border-box;
            margin: 0;
            padding: 0;
        }

        body {
            font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, 'Helvetica Neue', Arial, sans-serif;
            background: linear-gradient(135deg, var(--gray-100) 0%, var(--white) 100%);
            color: var(--gray-900);
            line-height: 1.5;
            min-height: 100vh;
        }

        /* ========================================
           HEADER & NAVIGATION
           ======================================== */
        header {
            background: var(--white);
            border-bottom: 3px solid var(--blue-primary);
            padding: 16px 24px;
            position: sticky;
            top: 0;
            z-index: 1000;
            box-shadow: var(--shadow-md);
        }

        .header-content {
            max-width: 1400px;
            margin: 0 auto;
            display: flex;
            justify-content: space-between;
            align-items: center;
            flex-wrap: wrap;
            gap: 16px;
        }

        .logo-section h1 {
            font-size: 1.5rem;
            font-weight: 700;
            color: var(--blue-primary);
            display: flex;
            align-items: center;
            gap: 10px;
        }

        .logo-section .subtitle {
            font-size: 0.85rem;
            color: var(--gray-500);
            margin-top: 2px;
        }

        .filter-tabs {
            display: flex;
            gap: 8px;
            flex-wrap: wrap;
        }

        .filter-tab {
            padding: 8px 16px;
            border: 2px solid var(--gray-300);
            background: var(--white);
            border-radius: 20px;
            font-size: 0.85rem;
            font-weight: 600;
            cursor: pointer;
            transition: all 0.2s ease;
            display: flex;
            align-items: center;
            gap: 6px;
        }

        .filter-tab:hover {
            border-color: var(--gray-500);
            background: var(--gray-100);
        }

        .filter-tab.active {
            border-color: var(--blue-primary);
            background: var(--blue-light);
            color: var(--blue-dark);
        }

        .filter-tab.urgent.active {
            border-color: var(--red-primary);
            background: var(--red-light);
            color: var(--red-dark);
        }

        .filter-tab.safe.active {
            border-color: var(--green-primary);
            background: var(--green-light);
            color: var(--green-dark);
        }

        /* ========================================
           MAIN CONTAINER
           ======================================== */
        main {
            max-width: 1400px;
            margin: 0 auto;
            padding: 24px;
        }

        .section-title {
            font-size: 1.1rem;
            font-weight: 700;
            color: var(--gray-700);
            margin: 24px 0 16px 0;
            padding-bottom: 8px;
            border-bottom: 2px solid var(--gray-300);
            display: flex;
            align-items: center;
            gap: 8px;
        }

        .card-grid {
            display: grid;
            grid-template-columns: repeat(auto-fill, minmax(420px, 1fr));
            gap: 20px;
        }

        /* ========================================
           CARD STYLES
           ======================================== */
        .card {
            background: var(--white);
            border-radius: var(--radius-lg);
            box-shadow: var(--shadow-sm);
            overflow: hidden;
            transition: all 0.3s cubic-bezier(0.4, 0, 0.2, 1);
            border: 1px solid var(--gray-300);
            border-left-width: 6px;
        }

        .card:hover {
            transform: translateY(-4px);
            box-shadow: var(--shadow-lg);
        }

        .card.hidden {
            display: none;
        }

        /* Card Color Variants */
        .card.urgent {
            border-left-color: var(--red-primary);
        }

        .card.urgent .card-header {
            background: linear-gradient(135deg, var(--red-light) 0%, #FFCDD2 100%);
            color: var(--red-dark);
        }

        .card.urgent .card-header::before {
            background: var(--red-primary);
        }

        .card.safe {
            border-left-color: var(--green-primary);
        }

        .card.safe .card-header {
            background: linear-gradient(135deg, var(--green-light) 0%, #C8E6C9 100%);
            color: var(--green-dark);
        }

        .card.safe .card-header::before {
            background: var(--green-primary);
        }

        .card.info {
            border-left-color: var(--blue-primary);
        }

        .card.info .card-header {
            background: linear-gradient(135deg, var(--blue-light) 0%, #BBDEFB 100%);
            color: var(--blue-dark);
        }

        .card.info .card-header::before {
            background: var(--blue-primary);
        }

        .card-header {
            padding: 14px 18px;
            font-weight: 700;
            font-size: 0.9rem;
            text-transform: uppercase;
            letter-spacing: 0.5px;
            display: flex;
            justify-content: space-between;
            align-items: center;
            position: relative;
        }

        .card-header .badge {
            font-size: 0.7rem;
            padding: 3px 8px;
            border-radius: 12px;
            background: rgba(255,255,255,0.7);
            font-weight: 600;
        }

        .card-body {
            padding: 18px;
        }

        /* ========================================
           CONTENT STYLES
           ======================================== */
        .card-body p {
            margin-bottom: 12px;
            font-size: 0.95rem;
        }

        .card-body ul, .card-body ol {
            padding-left: 20px;
            margin-bottom: 12px;
        }

        .card-body li {
            margin-bottom: 8px;
            font-size: 0.9rem;
            line-height: 1.5;
        }

        .alert-highlight {
            color: var(--red-primary);
            font-weight: 600;
            background: var(--red-light);
            padding: 2px 6px;
            border-radius: var(--radius-sm);
        }

        .safe-highlight {
            color: var(--green-dark);
            font-weight: 600;
            background: var(--green-light);
            padding: 2px 6px;
            border-radius: var(--radius-sm);
        }

        /* ========================================
           TABLES
           ======================================== */
        .data-table {
            width: 100%;
            border-collapse: collapse;
            margin-top: 12px;
            font-size: 0.85rem;
            background: var(--white);
            border-radius: var(--radius-sm);
            overflow: hidden;
        }

        .data-table th {
            background: var(--gray-100);
            padding: 10px 12px;
            text-align: left;
            font-weight: 600;
            color: var(--gray-700);
            border-bottom: 2px solid var(--gray-300);
            font-size: 0.75rem;
            text-transform: uppercase;
            letter-spacing: 0.3px;
        }

        .data-table td {
            padding: 10px 12px;
            border-bottom: 1px solid var(--gray-300);
        }

        .data-table tr:last-child td {
            border-bottom: none;
        }

        .data-table tr:hover td {
            background: var(--gray-100);
        }

        .table-positive {
            color: var(--green-dark);
            font-weight: 600;
        }

        .table-negative {
            color: var(--gray-500);
        }

        /* ========================================
           COLLAPSIBLE SECTIONS
           ======================================== */
        .expandable-section {
            border-top: 1px solid var(--gray-300);
        }

        .expand-btn {
            width: 100%;
            padding: 12px 18px;
            border: none;
            background: var(--gray-100);
            color: var(--blue-primary);
            font-weight: 600;
            font-size: 0.85rem;
            cursor: pointer;
            display: flex;
            justify-content: space-between;
            align-items: center;
            transition: background 0.2s ease;
        }

        .expand-btn:hover {
            background: var(--gray-300);
        }

        .expand-btn::after {
            content: '‚ñº';
            font-size: 0.7rem;
            transition: transform 0.3s ease;
        }

        .expand-btn.expanded::after {
            transform: rotate(180deg);
        }

        .expand-content {
            display: none;
            padding: 18px;
            background: #FAFAFA;
            border-top: 1px solid var(--gray-300);
        }

        .expand-content.show {
            display: block;
            animation: fadeIn 0.3s ease;
        }

        @keyframes fadeIn {
            from { opacity: 0; transform: translateY(-10px); }
            to { opacity: 1; transform: translateY(0); }
        }

        /* ========================================
           QUICK REFERENCE PANEL
           ======================================== */
        .quick-ref {
            background: var(--white);
            border-radius: var(--radius-lg);
            padding: 20px;
            margin-bottom: 24px;
            box-shadow: var(--shadow-sm);
            border: 1px solid var(--gray-300);
            border-left: 4px solid var(--blue-primary);
        }

        .quick-ref h3 {
            font-size: 1rem;
            color: var(--blue-dark);
            margin-bottom: 12px;
            display: flex;
            align-items: center;
            gap: 8px;
        }

        .quick-ref-grid {
            display: grid;
            grid-template-columns: repeat(auto-fit, minmax(200px, 1fr));
            gap: 16px;
        }

        .quick-ref-item {
            padding: 12px;
            background: var(--gray-100);
            border-radius: var(--radius-sm);
        }

        .quick-ref-item .label {
            font-size: 0.75rem;
            color: var(--gray-500);
            text-transform: uppercase;
            letter-spacing: 0.3px;
        }

        .quick-ref-item .value {
            font-size: 1rem;
            font-weight: 600;
            color: var(--gray-900);
            margin-top: 4px;
        }

        /* ========================================
           TWO COLUMN LAYOUT
           ======================================== */
        .two-column {
            display: grid;
            grid-template-columns: 1fr 1fr;
            gap: 20px;
        }

        /* ========================================
           FOOTER
           ======================================== */
        footer {
            text-align: center;
            padding: 32px 24px;
            margin-top: 40px;
            background: var(--gray-100);
            border-top: 1px solid var(--gray-300);
        }

        footer .disclaimer {
            max-width: 800px;
            margin: 0 auto;
            font-size: 0.8rem;
            color: var(--gray-500);
            line-height: 1.6;
        }

        footer .guideline-ref {
            margin-top: 12px;
            font-size: 0.75rem;
            color: var(--gray-500);
        }

        /* ========================================
           RESPONSIVE DESIGN
           ======================================== */
        @media (max-width: 900px) {
            .card-grid {
                grid-template-columns: 1fr;
            }

            .two-column {
                grid-template-columns: 1fr;
            }

            .quick-ref-grid {
                grid-template-columns: 1fr 1fr;
            }
        }

        @media (max-width: 600px) {
            header {
                padding: 12px 16px;
            }

            .header-content {
                flex-direction: column;
                align-items: flex-start;
            }

            .filter-tabs {
                width: 100%;
                overflow-x: auto;
                padding-bottom: 8px;
            }

            .filter-tab {
                white-space: nowrap;
                padding: 6px 12px;
                font-size: 0.8rem;
            }

            main {
                padding: 16px;
            }

            .quick-ref-grid {
                grid-template-columns: 1fr;
            }

            .data-table {
                font-size: 0.8rem;
            }
        }
    </style>
</head>
<body>

    <!-- HEADER -->
    <header>
        <div class="header-content">
            <div class="logo-section">
                <h1>
                    <svg width="28" height="28" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round">
                        <path d="M22 12h-4l-3 9L9 3l-3 9H2"/>
                    </svg>
                    GPA Rapid Reference
                </h1>
                <div class="subtitle">Granulomatosis with Polyangiitis (Wegener's) ‚Äî Evidence-Based Clinical Guide</div>
            </div>
            <div class="filter-tabs">
                <button class="filter-tab active" data-filter="all">All</button>
                <button class="filter-tab urgent" data-filter="urgent">üö® Emergency</button>
                <button class="filter-tab info" data-filter="info">üî¨ Diagnosis</button>
                <button class="filter-tab safe" data-filter="safe">üíä Treatment</button>
            </div>
        </div>
    </header>

    <!-- MAIN CONTENT -->
    <main>

        <!-- QUICK REFERENCE PANEL -->
        <section class="quick-ref">
            <h3>
                <svg width="20" height="20" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2">
                    <circle cx="12" cy="12" r="10"/>
                    <line x1="12" y1="16" x2="12" y2="12"/>
                    <line x1="12" y1="8" x2="12.01" y2="8"/>
                </svg>
                Quick Reference ‚Äî GPA at a Glance
            </h3>
            <div class="quick-ref-grid">
                <div class="quick-ref-item">
                    <div class="label">ANCA Pattern</div>
                    <div class="value" style="color: var(--blue-primary);">c-ANCA / PR3+</div>
                </div>
                <div class="quick-ref-item">
                    <div class="label">Classic Triad</div>
                    <div class="value">ENT + Lung + Kidney</div>
                </div>
                <div class="quick-ref-item">
                    <div class="label">First-Line Induction</div>
                    <div class="value" style="color: var(--green-dark);">Rituximab OR CYC</div>
                </div>
                <div class="quick-ref-item">
                    <div class="label">Untreated Survival</div>
                    <div class="value" style="color: var(--red-primary);">~5 months</div>
                </div>
            </div>
        </section>

        <!-- SECTION: EMERGENCY RED FLAGS -->
        <h2 class="section-title">
            <svg width="20" height="20" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2">
                <path d="M10.29 3.86L1.82 18a2 2 0 0 0 1.71 3h16.94a2 2 0 0 0 1.71-3L13.71 3.86a2 2 0 0 0-3.42 0z"/>
                <line x1="12" y1="9" x2="12" y2="13"/>
                <line x1="12" y1="17" x2="12.01" y2="17"/>
            </svg>
            Critical Red Flags ‚Äî Immediate Action Required
        </h2>

        <div class="card-grid">
            <!-- RED FLAG: Life-Threatening Manifestations -->
            <div class="card urgent" data-category="urgent">
                <div class="card-header">
                    <span>üö® Life-Threatening Manifestations</span>
                    <span class="badge">URGENT</span>
                </div>
                <div class="card-body">
                    <p>Immediate recognition and intervention is critical for these presentations:</p>
                    <ul>
                        <li><span class="alert-highlight">Diffuse Alveolar Hemorrhage (DAH)</span>: Hemoptysis, hypoxemia, new bilateral infiltrates, falling hemoglobin</li>
                        <li><span class="alert-highlight">Rapidly Progressive Glomerulonephritis (RPGN)</span>: Rising creatinine, RBC casts, proteinuria</li>
                        <li><span class="alert-highlight">Central Nervous System Vasculitis</span>: Stroke, seizures, altered mental status</li>
                        <li><span class="alert-highlight">Cardiac Involvement</span>: Myocarditis, pericarditis, heart failure</li>
                        <li><span class="alert-highlight">Mesenteric Ischemia</span>: Abdominal pain, GI bleeding</li>
                        <li><span class="alert-highlight">Limb/Digit Ischemia</span>: Critical limb threatening</li>
                    </ul>
                </div>
                <div class="expandable-section">
                    <button class="expand-btn" onclick="toggleExpand(this)">Emergency Protocol ‚ñº</button>
                    <div class="expand-content">
                        <p><strong>Immediate Actions (Within Minutes):</strong></p>
                        <ol>
                            <li><strong>Methylprednisolone 1g IV daily √ó 3 days</strong> (or 500mg if weight <50kg)</li>
                            <li><strong>Urgent Nephrology & Rheumatology consult</strong></li>
                            <li><strong>Consider Plasma Exchange</strong> if: Cr >5.7mg/dL OR DAH requiring ventilation</li>
                            <li><strong>Airway protection</strong> if DAH with respiratory failure</li>
                            <li><strong>Start empiric broad-spectrum antibiotics</strong> after cultures</li>
                        </ol>
                        <p style="margin-top: 12px;"><em>Reference: PEXIVAS Trial, ACR/EULAR 2021 Guidelines</em></p>
                    </div>
                </div>
            </div>

            <!-- RED FLAG: Airway Emergency -->
            <div class="card urgent" data-category="urgent">
                <div class="card-header">
                    <span>ü´Å Airway Emergency ‚Äî Subglottic Stenosis</span>
                    <span class="badge">CRITICAL</span>
                </div>
                <div class="card-body">
                    <p><strong>Clinical Presentation:</strong></p>
                    <ul>
                        <li>Stridor (inspiratory/expiratory)</li>
                        <li>Hoarseness, persistent cough</li>
                        <li>Dyspnea on exertion, orthopnea</li>
                        <li>Wheeze unresponsive to bronchodilators</li>
                    </ul>
                    <p style="margin-top: 12px;"><strong>Key Point:</strong> Laryngoscopy reveals circumferential red friable tissue narrowing the subglottis. Unlike asthma, flow-volume loop shows <span class="alert-highlight">fixed upper airway obstruction</span>.</p>
                </div>
                <div class="expandable-section">
                    <button class="expand-btn" onclick="toggleExpand(this)">Management Protocol ‚ñº</button>
                    <div class="expand-content">
                        <p><strong>Immediate Management:</strong></p>
                        <ol>
                            <li>ENT emergency consultation ‚Äî <span class="alert-highlight">secured airway if Stridor at rest</span></li>
                            <li><span class="safe-highlight">Systemic immunosuppressive therapy</span> for inflammatory component</li>
                            <li><span class="safe-highlight">Local therapy:</span> Intralesional glucocorticoid injection + dilatation</li>
                            <li>Tracheostomy only if definitive airway cannot be secured otherwise</li>
                        </ol>
                        <p style="margin-top: 12px;"><em>Note: Fibrotic stenoses respond poorly to immunosuppression alone.</em></p>
                    </div>
                </div>
            </div>

            <!-- RED FLAG: When NOT to Miss -->
            <div class="card urgent" data-category="urgent">
                <div class="card-header">
                    <span>‚ö†Ô∏è Don't Miss ‚Äî Easily Overlooked</span>
                    <span class="badge">VIGILANCE</span>
                </div>
                <div class="card-body">
                    <ul>
                        <li><span class="alert-highlight">Venous Thromboembolism (VTE)</span>: 16x increased risk during active disease. Any limb swelling/pain requires duplex ultrasound</li>
                        <li><span class="alert-highlight">Mononeuritis Multiplex</span>: Asymmetric sensorimotor neuropathy ‚Äî classic "foot drop" presentation</li>
                        <li><span class="alert-highlight">Silent Renal Involvement</span>: Normal creatinine does NOT exclude active glomerulonephritis ‚Äî always check UA</li>
                        <li><span class="alert-highlight">Subclinical Lung Disease</span>: 1/3 have asymptomatic lung involvement ‚Äî always image chest</li>
                        <li><span class="alert-highlight">Medication-Induced ANCA</span>: Propylthiouracil, minocycline, cocaine ‚Äî review medication history</li>
                    </ul>
                </div>
            </div>

            <!-- RED FLAG: Infection vs Relapse -->
            <div class="card urgent" data-category="urgent">
                <div class="card-header">
                    <span>ü¶† Infection vs Disease Relapse</span>
                    <span class="badge">DIAGNOSTIC CHALLENGE</span>
                </div>
                <div class="card-body">
                    <p><strong>Differentiating Features:</strong></p>
                    <table class="data-table">
                        <thead>
                            <tr>
                                <th>Feature</th>
                                <th>Infection</th>
                                <th>Relapse</th>
                            </tr>
                        </thead>
                        <tbody>
                            <tr>
                                <td>Fever</td>
                                <td>Common</td>
                                <td>Possible (low-grade)</td>
                            </tr>
                            <tr>
                                <td>Procalcitonin</td>
                                <td class="table-positive">Elevated</td>
                                <td class="table-negative">Normal</td>
                            </tr>
                            <tr>
                                <td>ANCA Titer</td>
                                <td>Variable</td>
                                <td>May rise (not reliable)</td>
                            </tr>
                            <tr>
                                <td>New Infiltrates</td>
                                <td>Common</td>
                                <td>Possible</td>
                            </tr>
                            <tr>
                                <td>Response to Antibiotics</td>
                                <td class="table-positive">Improves</td>
                                <td class="table-negative">No change</td>
                            </tr>
                        </tbody>
                    </table>
                    <p style="margin-top: 12px; font-size: 0.85rem;"><strong>Critical:</strong> Immunosuppressed patients may have blunted febrile response. Always obtain cultures before escalating immunosuppression.</p>
                </div>
            </div>
        </div>

        <!-- SECTION: DIAGNOSTICS -->
        <h2 class="section-title">
            <svg width="20" height="20" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2">
                <path d="M14.5 2H6a2 2 0 0 0-2 2v16a2 2 0 0 0 2 2h12a2 2 0 0 0 2-2V7.5L14.5 2z"/>
                <polyline points="14 2 14 8 20 8"/>
                <line x1="16" y1="13" x2="8" y2="13"/>
                <line x1="16" y1="17" x2="8" y2="17"/>
                <line x1="10" y1="9" x2="8" y2="9"/>
            </svg>
            Diagnostic Workup ‚Äî Initial Evaluation
        </h2>

        <div class="card-grid">
            <!-- DIAGNOSIS: ANCA Testing -->
            <div class="card info" data-category="info">
                <div class="card-header">
                    <span>üî¨ ANCA Testing Algorithm</span>
                    <span class="badge">DIAGNOSTIC</span>
                </div>
                <div class="card-body">
                    <p><strong>First-Line Test:</strong> Antigen-specific immunoassay for PR3 and MPO antibodies</p>
                    <table class="data-table">
                        <thead>
                            <tr>
                                <th>Result</th>
                                <th>Interpretation</th>
                            </tr>
                        </thead>
                        <tbody>
                            <tr>
                                <td class="table-positive">PR3-ANCA +</td>
                                <td><strong>GPA (High specificity ~90%)</strong></td>
                            </tr>
                            <tr>
                                <td>MPO-ANCA +</td>
                                <td>MPA more likely; can occur in GPA</td>
                            </tr>
                            <tr>
                                <td>Negative</td>
                                <td>Does NOT exclude GPA (9-16% negative)</td>
                            </tr>
                        </tbody>
                    </table>
                    <p style="margin-top: 12px;"><strong>Important Notes:</strong></p>
                    <ul>
                        <li>ANCA is <span class="safe-highlight">NOT reliable for monitoring disease activity</span></li>
                        <li>False positives: Infections, IBD, autoimmune hepatitis, malignancy, drugs</li>
                        <li>If negative but high suspicion ‚Üí consider tissue biopsy</li>
                    </ul>
                </div>
                <div class="expandable-section">
                    <button class="expand-btn" onclick="toggleExpand(this)">ANCA Patterns ‚ñº</button>
                    <div class="expand-content">
                        <p><strong>Indirect Immunofluorescence Patterns:</strong></p>
                        <table class="data-table">
                            <thead>
                                <tr>
                                    <th>Pattern</th>
                                    <th>Appearance</th>
                                    <th>Association</th>
                                </tr>
                            </thead>
                            <tbody>
                                <tr>
                                    <td class="table-positive">c-ANCA</td>
                                    <td>Cytoplasmic granular</td>
                                    <td><strong>GPA ‚Äî PR3</strong></td>
                                </tr>
                                <tr>
                                    <td>p-ANCA</td>
                                    <td>Perinuclear</td>
                                    <td>MPA/EGPA ‚Äî MPO</td>
                                </tr>
                                <tr>
                                    <td>Atypical</td>
                                    <td>Various</td>
                                    <td>Non-specific</td>
                                </tr>
                            </tbody>
                        </table>
                    </div>
                </div>
            </div>

            <!-- DIAGNOSIS: Required Initial Tests -->
            <div class="card info" data-category="info">
                <div class="card-header">
                    <span>üìã Required Initial Workup</span>
                    <span class="badge">MANDATORY</span>
                </div>
                <div class="card-body">
                    <p><strong>All patients with suspected GPA require:</strong></p>
                    <table class="data-table">
                        <thead>
                            <tr>
                                <th>Test</th>
                                <th>Finding in GPA</th>
                            </tr>
                        </thead>
                        <tbody>
                            <tr>
                                <td><strong>Urinalysis + Microscopy</strong></td>
                                <td>Hematuria, RBC casts, proteinuria ‚Äî earliest sign of renal involvement</td>
                            </tr>
                            <tr>
                                <td><strong>Chest CT</strong></td>
                                <td>Nodules (may cavitate), infiltrates, ground-glass (DAH)</td>
                            </tr>
                            <tr>
                                <td><strong>Serum Creatinine</strong></td>
                                <td>May be normal early ‚Äî does not exclude GN</td>
                            </tr>
                            <tr>
                                <td><strong>CRP/ESR</strong></td>
                                <td>Elevated (non-specific marker of inflammation)</td>
                            </tr>
                            <tr>
                                <td><strong>Complete Blood Count</strong></td>
                                <td>Anemia common; thrombocytopenia suggests alternative diagnosis</td>
                            </tr>
                        </tbody>
                    </table>
                    <p style="margin-top: 12px;"><span class="alert-highlight">Key Point:</span> Urinalysis is the <strong>earliest indicator</strong> of renal involvement ‚Äî often abnormal before creatinine rises.</p>
                </div>
            </div>

            <!-- DIAGNOSIS: Biopsy Yield -->
            <div class="card info" data-category="info">
                <div class="card-header">
                    <span>üß¨ Tissue Biopsy ‚Äî Site Selection</span>
                    <span class="badge">PATHOLOGY</span>
                </div>
                <div class="card-body">
                    <p><strong>Diagnostic Yield by Site:</strong></p>
                    <table class="data-table">
                        <thead>
                            <tr>
                                <th>Site</th>
                                <th>Yield</th>
                                <th>Typical Finding</th>
                            </tr>
                        </thead>
                        <tbody>
                            <tr>
                                <td><strong>Kidney</strong></td>
                                <td class="table-positive">High</td>
                                <td>Pauci-immune GN</td>
                            </tr>
                            <tr>
                                <td><strong>Open Lung Biopsy</strong></td>
                                <td class="table-positive">High</td>
                                <td>Granulomas + Vasculitis</td>
                            </tr>
                            <tr>
                                <td><strong>Skin</strong></td>
                                <td>Moderate</td>
                                <td>Leukocytoclastic vasculitis</td>
                            </tr>
                            <tr>
                                <td><strong>Sinus/Nasal</strong></td>
                                <td class="table-negative">Low <10%</td>
                                <td>Often non-specific</td>
                            </tr>
                            <tr>
                                <td><strong>Transbronchial</strong></td>
                                <td class="table-negative">Low <10%</td>
                                <td>Not reliable</td>
                            </tr>
                        </tbody>
                    </table>
                    <p style="margin-top: 12px;"><span class="safe-highlight">Recommendation:</span> Biopsy of affected organ (kidney > lung > skin). Negative sinus/transbronchial biopsy does NOT exclude GPA.</p>
                </div>
            </div>

            <!-- DIAGNOSIS: ACR/EULAR Criteria -->
            <div class="card info" data-category="info">
                <div class="card-header">
                    <span>üìê 2022 ACR/EULAR Classification Criteria</span>
                    <span class="badge">SCORING</span>
                </div>
                <div class="card-body">
                    <p><strong>Apply only after small/medium vessel vasculitis confirmed</strong></p>
                    <table class="data-table">
                        <thead>
                            <tr>
                                <th>Item</th>
                                <th>Points</th>
                            </tr>
                        </thead>
                        <tbody>
                            <tr>
                                <td>c-ANCA / Anti-PR3 positive</td>
                                <td class="table-positive">+5</td>
                            </tr>
                            <tr>
                                <td>Nasal involvement (bloody discharge, ulcers, crusting, septal perforation)</td>
                                <td class="table-positive">+3</td>
                            </tr>
                            <tr>
                                <td>Cartilaginous involvement (hoarseness, saddle nose, subglottic stenosis)</td>
                                <td class="table-positive">+2</td>
                            </tr>
                            <tr>
                                <td>Pulmonary nodules/cavitation on imaging</td>
                                <td class="table-positive">+2</td>
                            </tr>
                            <tr>
                                <td>Granuloma on biopsy</td>
                                <td class="table-positive">+2</td>
                            </tr>
                            <tr>
                                <td>Sinus imaging abnormalities</td>
                                <td>+1</td>
                            </tr>
                            <tr>
                                <td>Pauci-immune GN on biopsy</td>
                                <td>+1</td>
                            </tr>
                            <tr>
                                <td>p-ANCA / Anti-MPO positive</td>
                                <td style="color: var(--red-primary);">-1</td>
                            </tr>
                            <tr>
                                <td>Eosinophils ‚â•1.0 √ó 10‚Åπ/L</td>
                                <td style="color: var(--red-primary);">-4</td>
                            </tr>
                        </tbody>
                    </table>
                    <p style="margin-top: 12px;"><strong>Classification threshold: ‚â•5 points</strong></p>
                </div>
            </div>
        </div>

        <!-- SECTION: CLINICAL PRESENTATION -->
        <h2 class="section-title">
            <svg width="20" height="20" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2">
                <path d="M20 21v-2a4 4 0 0 0-4-4H8a4 4 0 0 0-4 4v2"/>
                <circle cx="12" cy="7" r="4"/>
            </svg>
            Clinical Presentation ‚Äî Classic Features
        </h2>

        <div class="card-grid">
            <!-- CLINICAL: Classic Triad -->
            <div class="card info" data-category="info">
                <div class="card-header">
                    <span>üéØ The Classic Triad</span>
                    <span class="badge">>90%</span>
                </div>
                <div class="card-body">
                    <ol>
                        <li>
                            <strong style="color: var(--blue-dark);">Upper Respiratory Tract (>90%)</strong>
                            <ul>
                                <li>Chronic sinusitis, nasal crusting, epistaxis</li>
                                <li>Otitis media, conductive hearing loss</li>
                                <li>Nasal septal perforation ‚Üí saddle nose deformity</li>
                                <li>Subglottic stenosis (can cause airway emergency)</li>
                            </ul>
                        </li>
                        <li>
                            <strong style="color: var(--blue-dark);">Lower Respiratory Tract</strong>
                            <ul>
                                <li>Cough, dyspnea, hemoptysis</li>
                                <li>Nodules (often cavitary) on imaging</li>
                                <li>Diffuse alveolar hemorrhage (life-threatening)</li>
                            </ul>
                        </li>
                        <li>
                            <strong style="color: var(--blue-dark);">Renal Involvement (80%)</strong>
                            <ul>
                                <li>Pauci-immune glomerulonephritis</li>
                                <li>Often asymptomatic until advanced</li>
                                <li>Rapidly progressive if untreated</li>
                            </ul>
                        </li>
                    </ol>
                </div>
            </div>

            <!-- CLINICAL: Other Manifestations -->
            <div class="card info" data-category="info">
                <div class="card-header">
                    <span>üëÅÔ∏è Other Organ Involvement</span>
                    <span class="badge">COMMON</span>
                </div>
                <div class="card-body">
                    <div class="two-column">
                        <div>
                            <p><strong>Ocular:</strong></p>
                            <ul>
                                <li>Scleritis/episcleritis</li>
                                <li>Proptosis (orbital granuloma)</li>
                                <li>Diplopia, vision loss</li>
                            </ul>
                            <p><strong>Cutaneous:</strong></p>
                            <ul>
                                <li>Palpable purpura</li>
                                <li>Nodules, ulcers</li>
                                <li>Hemorrhagic lesions</li>
                            </ul>
                        </div>
                        <div>
                            <p><strong>Neurological:</strong></p>
                            <ul>
                                <li>Mononeuritis multiplex</li>
                                <li>Peripheral neuropathy</li>
                                <li>Cranial neuropathies</li>
                            </ul>
                            <p><strong>Musculoskeletal:</strong></p>
                            <ul>
                                <li>Arthralgias (migratory)</li>
                                <li>Myalgias</li>
                                <li>Non-erosive arthritis</li>
                            </ul>
                        </div>
                    </div>
                </div>
            </div>

            <!-- CLINICAL: Differential Diagnosis -->
            <div class="card info" data-category="info">
                <div class="card-header">
                    <span>üîÄ Differential Diagnosis</span>
                    <span class="badge">EXCLUDE</span>
                </div>
                <div class="card-body">
                    <table class="data-table">
                        <thead>
                            <tr>
                                <th>Condition</th>
                                <th>Key Differentiators</th>
                            </tr>
                        </thead>
                        <tbody>
                            <tr>
                                <td><strong>Microscopic Polyangiitis (MPA)</strong></td>
                                <td>p-ANCA/MPO+, no granulomas, more renal dominant</td>
                            </tr>
                            <tr>
                                <td><strong>Eosinophilic GPA (EGPA)</strong></td>
                                <td>Asthma, eosinophilia >10%, cardiac involvement</td>
                            </tr>
                            <tr>
                                <td><strong>Goodpasture's Syndrome</strong></td>
                                <td>Anti-GBM antibodies+, no granulomas, no ENT involvement</td>
                            </tr>
                            <tr>
                                <td><strong>Infective Endocarditis</strong></td>
                                <td>Positive blood cultures, murmur, embolic phenomena</td>
                            </tr>
                            <tr>
                                <td><strong>Sarcoidosis</strong></td>
                                <td>Non-caseating granulomas, hilar LAD, ANCA negative</td>
                            </tr>
                            <tr>
                                <td><strong>Cocaine-Induced</strong></td>
                                <td>Midline destruction, positive toxicology, nasal perforation</td>
                            </tr>
                        </tbody>
                    </table>
                </div>
            </div>
        </div>

        <!-- SECTION: TREATMENT -->
        <h2 class="section-title">
            <svg width="20" height="20" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2">
                <path d="M19 14c1.49-1.46 3-3.21 3-5.5A5.5 5.5 0 0 0 16.5 3c-1.76 0-3 .5-4.5 2-1.5-1.5-2.74-2-4.5-2A5.5 5.5 0 0 0 2 8.5c0 2.3 1.5 4.05 3 5.5l7 7Z"/>
            </svg>
            Treatment Protocols ‚Äî Induction & Maintenance
        </h2>

        <div class="card-grid">
            <!-- TREATMENT: Induction Overview -->
            <div class="card safe" data-category="safe">
                <div class="card-header">
                    <span>üíä Remission Induction ‚Äî Severe Disease</span>
                    <span class="badge">LIFE/ORGAN THREATENING</span>
                </div>
                <div class="card-body">
                    <p><strong>All patients require:</strong></p>
                    <ol>
                        <li><span class="safe-highlight">High-dose corticosteroids</span> +</li>
                        <li><span class="safe-highlight">Immunosuppressive agent</span> (CHOOSE ONE):</li>
                    </ol>
                    <table class="data-table" style="margin-top: 12px;">
                        <thead>
                            <tr>
                                <th>Agent</th>
                                <th>Dosing</th>
                            </tr>
                        </thead>
                        <tbody>
                            <tr>
                                <td><strong>Rituximab (Preferred)</strong></td>
                                <td>375 mg/m¬≤ weekly √ó 4 OR 1g √ó 2 (Day 0, 14)</td>
                            </tr>
                            <tr>
                                <td><strong>Cyclophosphamide</strong></td>
                                <td>IV pulse (15mg/kg q2-3wks) OR oral (2mg/kg/day)</td>
                            </tr>
                        </tbody>
                    </table>
                    <p style="margin-top: 12px;"><em>Rituximab preferred over CYC per ACR guidelines (less toxic, equivalent efficacy). RAVE trial established non-inferiority.</em></p>
                </div>
                <div class="expandable-section">
                    <button class="expand-btn" onclick="toggleExpand(this)">Steroid Taper Protocol ‚ñº</button>
                    <div class="expand-content">
                        <table class="data-table">
                            <thead>
                                <tr>
                                    <th>Phase</th>
                                    <th>Duration</th>
                                    <th>Dose</th>
                                </tr>
                            </thead>
                            <tbody>
                                <tr>
                                    <td>Pulse</td>
                                    <td>Days 1-3</td>
                                    <td>Methylprednisolone 500-1000mg IV daily</td>
                                </tr>
                                <tr>
                                    <td>High-dose oral</td>
                                    <td>Weeks 1-4</td>
                                    <td>Prednisone 1mg/kg/day (max 80mg)</td>
                                </tr>
                                <tr>
                                    <td>Taper</td>
                                    <td>Months 2-6</td>
                                    <td>Gradual reduction to 5mg/day</td>
                                </tr>
                                <tr>
                                    <td>Target</td>
                                    <td>~5 months</td>
                                    <td>Prednisone 5mg/day or discontinue</td>
                                </tr>
                            </tbody>
                        </table>
                        <p style="margin-top: 12px;"><span class="alert-highlight">Reduced-dose regimen</span> (PEXIVAS) showed 60% less steroid exposure with non-inferior renal outcomes.</p>
                    </div>
                </div>
            </div>

            <!-- TREATMENT: Non-Severe Disease -->
            <div class="card safe" data-category="safe">
                <div class="card-header">
                    <span>üíä Remission Induction ‚Äî Non-Severe Disease</span>
                    <span class="badge">NON-LIFE THREATENING</span>
                </div>
                <div class="card-body">
                    <p><strong>When to use:</strong> No renal insufficiency, no DAH, no CNS involvement</p>
                    <table class="data-table">
                        <thead>
                            <tr>
                                <th>Agent</th>
                                <th>Notes</th>
                            </tr>
                        </thead>
                        <tbody>
                            <tr>
                                <td><strong>Methotrexate + Prednisone</strong></td>
                                <td>First-line (if Cr normal). Avoid if renal impairment.</td>
                            </tr>
                            <tr>
                                <td><strong>Rituximab + Prednisone</strong></td>
                                <td>Alternative, especially if concerns about MTX toxicity</td>
                            </tr>
                            <tr>
                                <td><strong>Mycophenolate + Prednisone</strong></td>
                                <td>Higher relapse rate; alternative if MTX/RTX contraindicated</td>
                            </tr>
                        </tbody>
                    </table>
                    <p style="margin-top: 12px;"><span class="alert-highlight">Contraindication:</span> Avoid cyclophosphamide in non-severe disease due to toxicity profile.</p>
                </div>
            </div>

            <!-- TREATMENT: Maintenance -->
            <div class="card safe" data-category="safe">
                <div class="card-header">
                    <span>üõ°Ô∏è Remission Maintenance</span>
                    <span class="badge">24-48 MONTHS</span>
                </div>
                <div class="card-body">
                    <p><strong>Start after successful remission induction (typically 3-6 months)</strong></p>
                    <table class="data-table">
                        <thead>
                            <tr>
                                <th>Agent</th>
                                <th>Dosing</th>
                                <th>Notes</th>
                            </tr>
                        </thead>
                        <tbody>
                            <tr>
                                <td class="table-positive"><strong>Rituximab</strong></td>
                                <td>500mg IV q6 months</td>
                                <td>Superior to AZA (MAINRITSAN trials)</td>
                            </tr>
                            <tr>
                                <td><strong>Azathioprine</strong></td>
                                <td>2mg/kg/day</td>
                                <td>Standard oral option</td>
                            </tr>
                            <tr>
                                <td><strong>Methotrexate</strong></td>
                                <td>15-25mg weekly</td>
                                <td>If renal function preserved</td>
                            </tr>
                        </tbody>
                    </table>
                    <p style="margin-top: 12px;"><strong>Duration:</strong> 24-48 months. Consider indefinite therapy for patients with relapsing disease.</p>
                </div>
            </div>

            <!-- TREATMENT: Special Situations -->
            <div class="card safe" data-category="safe">
                <div class="card-header">
                    <span>‚ö° Special Situations & Refractory Disease</span>
                    <span class="badge">COMPLEX</span>
                </div>
                <div class="card-body">
                    <table class="data-table">
                        <thead>
                            <tr>
                                <th>Scenario</th>
                                <th>Management</th>
                            </tr>
                        </thead>
                        <tbody>
                            <tr>
                                <td><strong>CYC cumulative >25g</strong></td>
                                <td>Switch to Rituximab for remission induction</td>
                            </tr>
                            <tr>
                                <td><strong>Rituximab failure</strong></td>
                                <td>Switch to Cyclophosphamide</td>
                            </tr>
                            <tr>
                                <td><strong>Pregnancy planning</strong></td>
                                <td>Prefer Rituximab over CYC; discuss fertility preservation</td>
                            </tr>
                            <tr>
                                <td><strong>Relapse on RTX</strong></td>
                                <td>Re-induce with RTX (often effective)</td>
                            </tr>
                            <tr>
                                <td><strong>IVIG-responsive</strong></td>
                                <td>Can be added as adjunct while waiting for other agents</td>
                            </tr>
                        </tbody>
                    </table>
                </div>
            </div>

            <!-- TREATMENT: Prophylaxis -->
            <div class="card safe" data-category="safe">
                <div class="card-header">
                    <span>üíâ Infection Prophylaxis</span>
                    <span class="badge">MANDATORY</span>
                </div>
                <div class="card-body">
                    <p><strong>Required for all patients on immunosuppression:</strong></p>
                    <table class="data-table">
                        <thead>
                            <tr>
                                <th>Indication</th>
                                <th>Prophylaxis</th>
                            </tr>
                        </thead>
                        <tbody>
                            <tr>
                                <td><strong>PCP (Pneumocystis)</strong></td>
                                <td>TMP-SMX 1 DS daily (or 3x/week) for all RTX/CYC patients</td>
                            </tr>
                            <tr>
                                <td><strong>High-dose steroids</strong></td>
                                <td>Consider TMP-SMX if >20mg prednisone + another agent</td>
                            </tr>
                            <tr>
                                <td><strong>Osteoporosis prevention</td>
                                <td>Calcium + Vitamin D; bisphosphonate if prednisone >3 months</td>
                            </tr>
                        </tbody>
                    </table>
                    <p style="margin-top: 12px;"><strong>Vaccinations:</strong> Give inactivated vaccines before B-cell depletion when possible. Avoid live vaccines during immunosuppression.</p>
                </div>
            </div>

            <!-- TREATMENT: Monitoring -->
            <div class="card safe" data-category="safe">
                <div class="card-header">
                    <span>üìä Drug Monitoring & Toxicity</span>
                    <span class="badge">SAFETY</span>
                </div>
                <div class="card-body">
                    <div class="two-column">
                        <div>
                            <p><strong>Cyclophosphamide:</strong></p>
                            <ul>
                                <li>Hemorrhagic cystitis (UA, symptoms)</li>
                                <li>Bone marrow suppression (CBC q2weeks initially)</li>
                                <li>Infertility (discuss sperm banking/ovarian suppression)</li>
                                <li>Bladder protection: Mesna with IV pulses</li>
                            </ul>
                        </div>
                        <div>
                            <p><strong>Rituximab:</strong></p>
                            <ul>
                                <li>Hypogammaglobulinemia (check IgG q3-6months)</li>
                                <li>Late-onset neutropenia</li>
                                <li>Infusion reactions (premedicate)</li>
                                <li>Reactivation: HBV, PML (rare)</li>
                            </ul>
                        </div>
                    </div>
                    <p style="margin-top: 12px;"><span class="alert-highlight">Maximum CYC lifetime exposure: 25g</span> ‚Äî beyond this, switch to RTX to limit toxicity.</p>
                </div>
            </div>
        </div>

        <!-- SECTION: PROGNOSIS -->
        <h2 class="section-title">
            <svg width="20" height="20" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2">
                <polyline points="22 12 18 12 15 21 9 3 6 12 2 12"/>
            </svg>
            Prognosis & Follow-Up
        </h2>

        <div class="card-grid">
            <!-- PROGNOSIS: Key Facts -->
            <div class="card info" data-category="info">
                <div class="card-header">
                    <span>üìà Prognostic Factors</span>
                    <span class="badge">OUTCOMES</span>
                </div>
                <div class="card-body">
                    <table class="data-table">
                        <thead>
                            <tr>
                                <th>Factor</th>
                                <th>Impact</th>
                            </tr>
                        </thead>
                        <tbody>
                            <tr>
                                <td>Untreated disease</td>
                                <td class="alert-highlight">Median survival: 5 months</td>
                            </tr>
                            <tr>
                                <td>With treatment</td>
                                <td class="safe-highlight">5-year survival: >80%</td>
                            </tr>
                            <tr>
                                <td>Age >50</td>
                                <td>Worse prognosis</td>
                            </tr>
                            <tr>
                                <td>Renal involvement at presentation</td>
                                <td>Worse renal outcomes</td>
                            </tr>
                            <tr>
                                <td>PR3-ANCA positive</td>
                                <td>Higher relapse risk (vs MPO)</td>
                            </tr>
                        </tbody>
                    </table>
                    <p style="margin-top: 12px;"><strong>Course:</strong> Chronic relapsing-remitting. Most patients experience disease- or treatment-related morbidity over time.</p>
                </div>
            </div>

            <!-- PROGNOSIS: Disease Activity Assessment -->
            <div class="card info" data-category="info">
                <div class="card-header">
                    <span>üìã Disease Activity Definitions</span>
                    <span class="badge">ACR/EULAR</span>
                </div>
                <div class="card-body">
                    <table class="data-table">
                        <thead>
                            <tr>
                                <th>Term</th>
                                <th>Definition</th>
                            </tr>
                        </thead>
                        <tbody>
                            <tr>
                                <td><strong>Active Disease</strong></td>
                                <td>New/worsening signs/symptoms attributable to GPA (not damage)</td>
                            </tr>
                            <tr>
                                <td><strong>Severe</strong></td>
                                <td>Life/organ-threatening manifestations (DAH, GN, CNS)</td>
                            </tr>
                            <tr>
                                <td><strong>Non-Severe</strong></td>
                                <td>Without life/organ-threatening features (sinusitis, mild arthritis)</td>
                            </tr>
                            <tr>
                                <td><strong>Remission</strong></td>
                                <td>No GPA-attributable signs/symptoms (on or off immunosuppression)</td>
                            </tr>
                            <tr>
                                <td><strong>Refractory</strong></td>
                                <td>Persistent active disease despite appropriate therapy</td>
                            </tr>
                            <tr>
                                <td><strong>Relapse</strong></td>
                                <td>Recurrence of active disease after remission</td>
                            </tr>
                        </tbody>
                    </table>
                    <p style="margin-top: 12px;"><strong>Key Distinction:</strong> <em>Active disease</em> vs <em>Damage</em> (permanent scarring from prior inflammation). Treatment decisions require careful differentiation.</p>
                </div>
            </div>
        </div>

    </main>

    <!-- FOOTER -->
    <footer>
        <p class="disclaimer">
            <strong>DISCLAIMER:</strong> This clinical reference tool is for educational purposes only and should not replace clinical judgment. 
            Always verify dosages, contraindications, and institutional protocols. Treatment decisions should be made in consultation with 
            rheumatology/vascularitis specialists. Information based on ACR/EULAR 2021 Guidelines and current evidence.
        </p>
        <p class="guideline-ref">
            Key References: ACR/EULAR 2021 AAV Guidelines | PEXIVAS Trial (NEJM 2020) | RAVE Trial (NEJM 2013) | MAINRITSAN Trials
        </p>
    </footer>

    <script>
        // ========================================
        // FILTER FUNCTIONALITY
        // ========================================
        document.addEventListener('DOMContentLoaded', function() {
            const filterTabs = document.querySelectorAll('.filter-tab');
            const cards = document.querySelectorAll('.card');

            filterTabs.forEach(tab => {
                tab.addEventListener('click', function() {
                    // Update active state
                    filterTabs.forEach(t => t.classList.remove('active'));
                    this.classList.add('active');

                    // Filter cards
                    const filter = this.getAttribute('data-filter');
                    cards.forEach(card => {
                        if (filter === 'all') {
                            card.classList.remove('hidden');
                        } else {
                            if (card.getAttribute('data-category') === filter) {
                                card.classList.remove('hidden');
                            } else {
                                card.classList.add('hidden');
                            }
                        }
                    });
                });
            });

            // ========================================
            // CARD EXPAND/COLLAPSE
            // ========================================
            // Initialize expand buttons state
            const expandBtns = document.querySelectorAll('.expand-btn');
            expandBtns.forEach(btn => {
                btn.addEventListener('click', function() {
                    this.classList.toggle('expanded');
                });
            });
        });

        function toggleExpand(button) {
            const content = button.nextElementSibling;
            content.classList.toggle('show');
            button.classList.toggle('expanded');
            
            // Update button text
            if (content.classList.contains('show')) {
                button.textContent = button.textContent.replace('‚ñº', '‚ñ≤');
            } else {
                button.textContent = button.textContent.replace('‚ñ≤', '‚ñº');
            }
        }

        // ========================================
        // SEARCH FUNCTIONALITY (Optional Enhancement)
        // ========================================
        document.addEventListener('keydown', function(e) {
            // Press '/' to focus on first filter tab
            if (e.key === '/' && document.activeElement.tagName !== 'INPUT') {
                e.preventDefault();
                document.querySelector('.filter-tab[data-filter="all"]').click();
            }
        });
    </script>
</body>
</html>
